TY - JOUR
T1 - Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome
AU - Jabs, Douglas A.
AU - Van Natta, Mark L.
AU - Sezgin, Efe
AU - Pak, Jeong Won
AU - Danis, Ronald
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Financial Disclosures: Douglas A. Jabs: Applied Genetic Technologies Corporation, Alachua, Florida (Data and Safety Monitoring Committee), Novartis Pharmaceuticals, Basel, Switzerland (Data and Safety Monitoring Committee), and Santen, Inc, Emeryville, California (consultant). Funding/Support: Supported by cooperative agreements from the National Eye Institute, the National Institutes of Health, Bethesda, Maryland, to the Icahn School of Medicine at Mount Sinai, New York, New York (U10 EY 08052); The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland (U10 EY 08057); and the University of Wisconsin, Madison School of Medicine, Madison, Wisconsin (U10 EY 08067); and in part by the Johns Hopkins Center for AIDS Research (P30 AI 094189), Baltimore, Maryland, co-funded by the National Institute of Allergy and Infectious Diseases; the National Cancer Institute; the National Institute of Child Health and Development; the National Heart, Lung, and Blood Institute; the National Institute of Drug Abuse; the National Institute of Mental Health; the National Institute of Aging; the Fogarty International Center; the National Institute of General Medical Sciences; the National Institute of Diabetes and Digestive and Kidney Diseases; and the Office of AIDS Research, the National Institutes of Health, Bethesda, Maryland. All authors attest that they meet the current ICMJE requirements to qualify as authors.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Purpose To evaluate the prevalence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS). Design Cross-sectional study of patients with AIDS enrolled in the Longitudinal Study of the Ocular Complications of AIDS. Methods Intermediate-stage AMD was determined from enrollment retinal photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study grading system. Graders were masked as to clinical data. Results Of 1825 participants with AIDS and no ocular opportunistic infections, 9.9% had intermediate-stage AMD. Risk factors included age, with an odds ratio (OR) of 1.9 (95% confidence interval [CI] 1.6, 2.3, P <.001) for every decade of age; the prevalence of AMD ranged from 4.0% for participants 30-39 years old to 24.3% for participants =60 years old. Other risk factors included the human immunodeficiency virus (HIV) risk groups of injection drug use (OR = 2.4, 95% CI 1.5, 3.9, P <.001) or heterosexual contact (OR = 1.9, 95% CI 1.3, 2.8, P =.001). Compared with the HIV-uninfected population in the Beaver Dam Offspring Study, there was an approximate 4-fold increased age-adjusted prevalence of intermediate-stage AMD. Conclusions Patients with AIDS have an increased age-adjusted prevalence of intermediate-stage AMD compared with that found in a non-HIV-infected cohort evaluated with similar methods. This increased prevalence is consistent with the increased prevalence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infected persons when compared to non-HIV-infected persons.
AB - Purpose To evaluate the prevalence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS). Design Cross-sectional study of patients with AIDS enrolled in the Longitudinal Study of the Ocular Complications of AIDS. Methods Intermediate-stage AMD was determined from enrollment retinal photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study grading system. Graders were masked as to clinical data. Results Of 1825 participants with AIDS and no ocular opportunistic infections, 9.9% had intermediate-stage AMD. Risk factors included age, with an odds ratio (OR) of 1.9 (95% confidence interval [CI] 1.6, 2.3, P <.001) for every decade of age; the prevalence of AMD ranged from 4.0% for participants 30-39 years old to 24.3% for participants =60 years old. Other risk factors included the human immunodeficiency virus (HIV) risk groups of injection drug use (OR = 2.4, 95% CI 1.5, 3.9, P <.001) or heterosexual contact (OR = 1.9, 95% CI 1.3, 2.8, P =.001). Compared with the HIV-uninfected population in the Beaver Dam Offspring Study, there was an approximate 4-fold increased age-adjusted prevalence of intermediate-stage AMD. Conclusions Patients with AIDS have an increased age-adjusted prevalence of intermediate-stage AMD compared with that found in a non-HIV-infected cohort evaluated with similar methods. This increased prevalence is consistent with the increased prevalence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infected persons when compared to non-HIV-infected persons.
UR - http://www.scopus.com/inward/record.url?scp=84929130172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929130172&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2015.01.037
DO - 10.1016/j.ajo.2015.01.037
M3 - Article
C2 - 25769246
AN - SCOPUS:84929130172
VL - 159
SP - 1115-1122.e1
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 6
ER -